The global market for Pharma ADMET Testing is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Pharma ADMET Testing market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Pharma ADMET Testing market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Pharma ADMET Testing market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Pharma ADMET Testing market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Pharma ADMET Testing players cover CMIC Holdings, Charles River Laboratories, WuXi AppTec, Promega Corporation and Merck KGaA, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This latest report provides a deep insight into the global Pharma ADMET Testing market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Pharma ADMET Testing market, with both quantitative and qualitative data, to help readers understand how the Pharma ADMET Testing market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
The study segments the Pharma ADMET Testing market and forecasts the market size by Type (In Vivo ADMET Testing and In Vitro ADMET Testing,), by Application (Systemic Toxicity Testing, Hepatotoxicity Testing, Renal Toxicity Testing and Neurotoxicity Testing), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
In Vivo ADMET Testing
In Vitro ADMET Testing
Segmentation by application
Systemic Toxicity Testing
Renal Toxicity Testing
Segmentation by region
Middle East & Africa
Major companies covered
Charles River Laboratories
Biovia (Dassault Systemes)
Chapter 1: Scope of Pharma ADMET Testing, Research Methodology, etc.
Chapter 2: Executive Summary, global Pharma ADMET Testing market size and CAGR, Pharma ADMET Testing market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Pharma ADMET Testing revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Pharma ADMET Testing revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Pharma ADMET Testing market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including CMIC Holdings, Charles River Laboratories, WuXi AppTec, Promega Corporation, Merck KGaA, Agilient Technologies, Biovia (Dassault Systemes), Cyprotex Limited and Bio-Rad Laboratories and etc.
Chapter 14: Research Findings and Conclusion